** Shares of Divi's Laboratories DIVI.NS fall 1.7% to
4,893 rupees
** Stock among top losers on Nifty 50 index .NSEI , which
is down 1.81%
** DIVI saw a 21% rise in Q1 consolidated net profit,
however analysts flag slow margin recovery
** Co's generic API business reported a muted growth of ~1%
Y/Y, with the increase in volumes being offset by steep price
erosion, said analysts at Antique Stock Broking
** Continued pricing pressure in generic-APIs, overheads at
Kakinada plant and custom-synthesis project would drag margins-
Ambit Capital Research
** Twenty-two analysts covering the stock on avg have a
"hold" rating; median PT is 3,965 rupees - LSEG data
** Stock up 7% so far this qtr, vs a 10.6% rise in Nifty
pharma index .NIPHARM
(Reporting by Ashna Teresa Britto in Bengaluru)
((AshnaTeresa.Britto@thomsonreuters.com ; ( +91 8078332441))